Hogan Lovells Publications
Life sciences and health care horizons 2021
23 February 2021
PartnerNew York
Email adam.golden@hoganlovells.com
Phone +1 212 918 3636
Fax +1 212 918 3100
Practice groupCorporate & Finance
Head of the Corporate practice group in New York, Adam Golden advises life sciences companies on some of their most important transactions. Clients turn to Adam for his dual skillset, which combines his strengths as an M&A and corporate lawyer with those of an IP transactions lawyer. This enables him to represent pharmaceutical, biotech, and medical device companies in the full scope of transactions that are common to this sector.
Over his career, Adam has advised clients on M&A, license and collaboration deals, venture capital financings, and commercial transactions. Frequently, clients seek his advice on hybrid transactions such as M&A transactions with back-end milestone payments or contingent value rights, options to acquire companies or technology, and product divestitures. He also advises clients on the transition service, manufacturing and supply, and other operational agreements that often accompany these transactions.
Adam is recognized as a leading practitioner in Chambers Global, Chambers USA, Legal 500 US, Who's Who Legal, LMG Life Sciences, and IAM Patent 1000. In 2018, he was named M&A Attorney of the Year by LMG Life Sciences, and a Life Sciences MVP by Law360.
Corporate and M&A, Notable Practitioner
IFLR1000
Pharmaceuticals and Life Sciences, Notable Practitioner
IFLR1000
Life Sciences: Corporate/Commercial (USA)
Chambers Global
Life Sciences: Corporate/Commercial (Nationwide)
Chambers USA
Life Sciences: Corporate/commercial (Global-wide)
Chambers Global
Healthcare: Life Sciences, Leading Lawyer
Legal 500 US
M&A/Corporate and Commercial: M&A: Large Deals ($1bn+)
Legal 500 US
Life Sciences Star - Finance & Transactional
LMG Life Sciences
Life Sciences - Transactional
Who's Who Legal
The World's Leading Patent Practitioners
IAM Patent 1000
Education
J.D., New York University School of Law, 1990
A.B., Princeton University, 1986
Bar admissions and qualifications
New York
Massachusetts
Novartis on its acquisition of IFM Tre for up to US$1.6bn and its option to acquire IFM Due for up to US$840m.
Celgene Corporation, on its US$9bn acquisition of Juno Therapeutics, a clinical-stage cell immunotherapy company.
Novartis, on its US$8.7bn acquisition of AveXis Inc., a clinical-stage gene therapy biotech company.
Shire on the ex-U.S. aspects of its US$2.4bn oncology business sale to Servier S.A.S.
Celgene Corporation, on its acquisition of Impact Biomedicines for up to US$7bn, a clinical stage company developing fedratinib for myelofibrosis.
Chase Pharmaceuticals on its sale to Allergan for up to US$1bn.
Allergan on its US$40.5bn generics divestiture to Teva Pharmaceuticals.
Alcon Laboratories on its acquisitions of Encore Vision, RxSight, and Transcend Medical.
Novartis in the acquisition from GSK of rights to Arzerra® (ofatumumab) for auto-immune indications for more than US$1bn.
Kite, a Gilead company, in an up to US$3bn deal to access Sangamo Therapeutics' zinc finger nuclease technology.
Celgene on strategic collaborations and equity investments, including with Kyn Therapeutics, Ex Scientia, Obsidian Therapeutics, Jounce Therapeutics, and Skyhawk Therapeutics.
Gilead Sciences on its US$150m collaboration with Agenus to develop and commercialize up to five novel immuno-oncology therapies.
Novartis on its collaboration with Cellular Biomedicine Group to support the introduction of the CAR-T cell therapy Kymriah® (tisagenlecleucel) in China.
Gilead Sciences on its strategic partnership with Goldfinch Bio, to develop and commercialize innovative therapeutics for kidney diseases.
Bausch Health (formerly Valeant) on the sale of Dendreon Pharmaceuticals to the Sanpower Group Co., Ltd., one of the largest privately owned conglomerates in China.
Gilead Sciences on its strategic collaboration with Tango Therapeutics, to develop and commercialize innovative targeted immuno-oncology treatments for cancer.
Novartis on strategic collaborations with Surface Therapeutics, Xencor, and Homology Medicines.
Novartis in connection with its landmark portfolio transformation transactions with GSK and Eli Lilly worth more than US$23bn.
Buyers and sellers of FDA priority review vouchers.
Hogan Lovells Publications
23 February 2021
Published Works
02 February 2021
Press Releases
23 November 2020
Press Releases
10 November 2020
Awards and Rankings
24 September 2020
Press Releases
23 September 2020